Summary

• Buy Recommendation: Pfizer shows strong growth potential and income appeal.
• Q3 Performance: 32% year-over-year growth with expanding non-COVID revenue.
• Strategic Focus: Shifting to oncology and weight loss treatments to drive future growth.
• High Dividend Yield: Attractive for income-focused investors.
• Debt Reduction: Strengthens financial stability and flexibility.
• Long-Term Potential: Diversified pipeline supports growth beyond COVID-related products.

Introduction & Pfizer’s Q3 Performance

Pfizer delivered strong third quarter 2024 financial results. According to an article published on Pfizer Investor Insights, “The company reported revenues of $17.7 billion in the third quarter, representing 32% year-over-year growth. Excluding the company’s COVID-19 products, revenues were $13.6 billion, reflecting an operational increase of 14% compared with the prior-year quarter. Third quarter revenue growth was driven primarily by a combination of contributions from Pfizer’s Oncology products, key in-line products, recent commercial launches, as well as heightened demand for its COVID-19 oral treatment. This quarter marks Pfizer’s impressive third consecutive quarter of growth in 2024. Based on the recent quarter performance, the company once again raised its full-year 2024 revenue guidance and adjusted diluted EPS guidance. The company once again increased its full-year 2024 sales projection and modified diluted EPS guidance as a result of the last quarter's success. 

COVID Franchise & Non-COVID Growth Options

 Pfizer’s current focus on oncology and other rare diseases highlights the transition from its reliance on COVID products. Pfizer must now shift its focus to other areas due to a consistent decline in revenue from its COVID products. According to CNBC, Pfizer’s revenue dropped by 33% in 2023. While people in the market are concerned about Pfizer's post-COVID growth because of the patent expirations and increased competition, Pfizer is addressing these challenges by investing heavily in R&D and strategic acquisitions. Pfizer is also leveraging mRNA technology, proven in its COVID vaccine, for other potential vaccines and genetic treatments to provide further success showing future promise . With a strong balance sheet and a diversified portfolio, Pfizer is focusing to maintain robust growth despite the loss of COVID-related revenue

Guidance & Capital Allocation Framework

Pfizer’s guidance for 2024 project revenues estimates $58.5 and $61.5 billion, reflecting a moderated outlook compared to last year as the demand for COVID-19 products like Paxlovid stabilizes. This outlook shows shifts in COVID-19 product demand, including Paxlovid and Comirnaty, expected to bring in about 8 billion dollars. Despite this, Pfizer’s portfolio is positioned for growth between 8-10% outside COVID-19/pandemic-related products with the recent acquisition of Seagen. Despite decreasing legacy COVID-19 revenues, Pfizer is focused on scaling the oncology, vaccines, and anti-infective products/segments to increase revenue. In cash management, Pfizer is showing a conservative approach, opting not to repurchase shares of 2024 and instead choosing to prioritize their debt reduction with the recent acquisition of Seagen. The company’s $4 billion cost-saving initiative, which is intended to restore operating margins to pre-COVID levels, emphasizes the company’s dedication to increasing profitability even as its expenses rise. This strategy is backed by a very long-standing demand for their products. Which Pfizer expects to leverage for stable revenue growth. Pfizer’s conservative capital allocation strategy shows a balance between reinvesting in growth and maintaining some flexibility to address future operational needs, signaling a focus on performance as the global health markets shift and evolve from a need for COVID-19 products to products focusing on oncology and many other things.

Pipeline Overview & Oncology Segment

Pfizer's future expansion is mostly focused upon its late-stage oncology pipeline, especially since buying Seagen in 2023 to expand its targeted cancer therapies and antibody-drug conjugates (ADCs). ADC Sigvotatug vedotin for non-small cell lung cancer, prostate cancer medicines like PACDEV with KEYTRUDA, and breast cancer medications like abemaciclib and PF-07248144 are important assets. Pfizer expects many regulatory submissions, anticipated peak sales of $10 billion from oncology by the late 2020s, and the further expansion of indications for well-known medications like IBRANCE and 56666 TULISA.

New Markets: Weight Loss Drugs 

Pfizer has recently entered the weight loss drug market with Danuglipron, an oral glp-1 receptor agonist whose introduction is well timed as there is increasing demand in the market for prescription drugs for weight loss. Promising results have been experienced in the Phase 2 trials of Danuglipron, which also demonstrated a clinically significant placebo-adjusted loss of weight and ease of tolerating the drug. It remains to be seen whether this high rate of discontinuation of the treatment can be explained entirely by the broad range of gastrointestinal effects experienced. Pfizer has now prioritized a once-a-day modified-release version of Danuglipron that they hope to improve further in 2024. This formulation may lead to increased tolerability and improved patient adherence, hence presenting itself into a market characterized by injectables. In comparison to Eli Lilly's oral candidate and Astra's lower-rate offering, Pfizer hopes to launch funnel and Danuglipron in the next few years. Demand for weight loss medications is presently quite high owing to growing understanding of obesity's accompanying health threats as well as better treatment options resulting in considerable growth potential within the market. If approved, Danuglipron could offer a major source of revenue and allow time-poor patients a simpler oral method of taking GLP-1 medications , which represents a new strategy for companies like Novo Nordisk and Eli Lilly, who currently lead in the market. 

Capital Allocation & Debt Reduction Strategy

In Pfizer’s strategic shift toward long-term growth, capital allocation and debt reduction have become critical focal points. Following its recent acquisition of Seagen, Pfizer has prioritized lowering its debt, demonstrating a cautious approach to capital management. Rather than share repurchases, Pfizer has opted to channel resources into reducing its debt burden, a move designed to strengthen its balance sheet and enhance financial flexibility. This approach is supported by the company’s $4 billion cost-saving initiative aimed at improving operating margins, which aligns with the goal of achieving greater profitability in a post-COVID revenue landscape. By prioritizing debt reduction, Pfizer not only bolsters investor confidence but also positions itself to reinvest in key growth areas, especially in oncology and other high-potential therapeutic areas.

Dividend Policy and Shareholder Returns

In Pfizer’s most recent quarterly report, they expressed their goal of bolstering the shareholder value as much as possible. They prioritize increasing the number of share buybacks, reducing the company’s debt, and improving the value of their dividends. Dividend yield is calculated by dividing the annual dividends per share by the price of the shares. This metric communicates what percentage of the share price the dividend is. A higher dividend yield indicates that the company's dividends are worth the share's price. Pfizer’s current dividend yield is 6.00%, which is higher than average. As of the YTD, the annual dividend is $4.96, and the dividend of the recent quarter is $0.42. In the past two quarters, Pfizer has spent $273.04 on share buybacks. These share buybacks increase the value of a Pfizer share which benefits current investors. Based on recent company goals, the amount of shares repurchased by the company will increase. Investors can maximize their profit by investing as soon as possible, as Pfizer’s dividend policy benefits income investors due to the dividends the company distributes each quarter. When compared to peer companies like Johnson and Johnson, Novo Nordisk, and AbbVie Inc, Pfizer has the highest dividend yield and payout ratio, making it the optimal company to invest in.

Comparisons of Pfizer, Johnson & Johnson, AbbVie Inc., and Novo Nordisk

Research and Development Focus in Oncology

Pfizer’s oncology efforts are led by innovative treatments such as Elranatamab, known as Elrexfio. Approved last year, Elrexifo targets patients that suffer from a rare and incurable blood cancer that affects myeloma cells. This disease currently impacts around 160,000 people worldwide and accumulates around 34,000 new diagnoses annually in the U.S. alone. Elrexifo aims to extend the amount of time patients have before their condition worsens. According to The Independent, the treatment was recently endorsed by the National Institute for Health and Care Excellence (NICE) in the UK. It is estimated by NICE themselves that about 700 people will benefit from this recommendation. It will only help a handful of patients because of the restrictions that reduce accessibility, however, efforts are underway to broaden its reach. Globally, Elrexifo is a key contributor of Pfizer’s projected oncology sales, which totaled over $12 billion in 2023. So far, their oncology revenue, combined with that of non-COVID products, has totaled over $13.6 billion in Q3 2024. These products are seeing a growth rate of 14% compared to last year. Aside from Elrexifo, Pfizer also intends to boost its oncology sector by investing in next-gen cancer therapies like immuno-oncology, further researching potential cancer treatments, and striking partnerships with biotech firms. These factors suggest a promising future for Pfizer’s role in oncology, making the company a compelling investment opportunity going forward, even with COVID out of the picture.

Competitive Landscape in Weight Loss Market

Pfizer’s entry into the weight loss drug market with Danuglipron provides it with a foothold against key competitors like Eli Lilly. Danuglipron’s oral formulation offers a unique advantage in a field dominated by injectables, potentially boosting patient adherence. While competitors like Eli Lilly and Novo Nordisk hold substantial market shares, Pfizer's innovation in GLP-1 delivery could capture significant demand, especially if its modified-release formulation proves successful.

Profitability Metrics & Investor Appeal

Pfizer’s profitability metrics reveal a mixed picture for long-term investors. While its gross profit and operating income are substantial, translating into a gross profit of $42.68 billion this year with a $4.2 billion net income, profitability ratios such as ROE (declining at 28%) and ROIC (14%) signal potential weaknesses in value generation for shareholders. Additionally, Pfizer’s profitability score is a modest 58/100, trailing behind competitors like Johnson & Johnson, Roche, and Eli Lilly, which have higher scores and better net income margins despite lower gross profits. Pfizer’s EBITDA margins reflect solid cash-generating ability, but declining profitability metrics suggest a need to boost efficiency or reduce costs to enhance returns. Pfizer’s forward dividend yield, which appeals to income-focused investors, remains a strong draw, yet the declining ROE and ROIC may lessen its attractiveness as a sustainable long-term investment compared to its more efficient peers.

Valuation Analysis

Two factors that can be used to conduct an in-depth analysis for the valuation of Pfizer are forward EBITDA and PEG ratios. These can be used to compare Pfizer to industry standards. Currently, their EBITDA margin benchmark against competitors is 30.7%. Pfizer is relatively higher compared to industry standards, emphasizing strong profitability. Additionally, Pfizer’s PEG ratio is 1.47. Compared to industry standards, Pfizer is well exceeding in this category reflecting how it could be potentially overvalued. Therefore, their current valuation reflects strong growth potential according to EBITDA but questionable growth potential according to PEG ratios. In addition, Pfizer’s stance in the healthcare industry allows them to dominate but also provides risks as their COVID-19- revenue is slowly declining. Ultimately, Pfizer's strong EBITDA margin and dominant industry position make it a unique portfolio addition, as it offers stability and growth potential despite concerns over COVID-19 revenue decline and a high PEG ratio.

Conclusion: Investment Thesis/ TLDR

Buy: Pfizer’s strong Q3 growth, high dividend, and strategic focus on cancer and weight loss treatments make it a stable, income-friendly investment with solid long-term potential.

Has anyone been watching XFOR? Seems like they may start making money soon… they’ll have a drug on the market soon and they just started giving out more stock to employees. Could be a big money opportunity, wondering if anyone else has any thoughts.

Mainz Biomed's ($MYNZ) upcoming EGM could have a notable impact on stock performance. EGMs often address significant business strategies or urgent updates, which can affect investor sentiment. For $MYNZ, news around advancements in their cancer detection pipeline or regulatory progress (e.g., FDA approvals) could boost stock prices. Conversely, any mentioned challenges or delays might create downward pressure.

Given the stock's volatility, reflected in its 52-week range from $0.1850 to $2.5070 and current EPS (TTM) of -1.1100, keeping an eye on EGM outcomes is essential. Investors should watch for key announcements and shifts in trading volume.

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026--

https://www.businesswire.com/news/h...r-2024-Financial-Results-and-Business-Updates

--On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025--

--Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--

RFK Jr. Pledges To Legalize Marijuana And Psychedelics, Using Revenue To Fund Farms Where People Recovering From Drug Addiction Can Grow Organic Food

https://www.marijuanamoment.net/rfk...ng-from-drug-addiction-can-grow-organic-food/

“I would legalize psychedelic drugs—some form of legalization,” he said, adding that he doesn’t necessarily envision a commercial market where anyone could visit a shop to buy the substances, but that there should be regulated access”

Hey guys, I guess there are some Ginkgo investors here. If you missed it, they just partnered with Novus International to develop new feed additives that would help lower animal feeding costs and improve the quality of the products. Hopefully, this will help them move on from the whole “fraud” drama they had a few years ago.

For the newbies: a few years ago, Scorpion Capital accused Ginkgo of being one of the worst frauds in 20 years and could be compared to other major biotech frauds. They presented interviews with former and current employees. And they also said that most of Ginkgo’s revenue comes from related-party transactions.

All these caused a DOJ’s investigation for financial misconduct. But, the good news is that DNA decided to resolve it and pay $17M to the investors. They are now taking claims, and the deadline is in two weeks, so if you were an investor back then, you can check it out.

Now, DNA is partnering with some different companies like Novus or Vitalis in Brazil to increase its reach, so we’ll see how this perspective works out for them.  

Anyways, what do you think about this new collab? And has anyone here had $DNA when this scandal happened? If so, how much were your losses?

From established players to up-and-coming firms, Canada's pharmaceutical company is diverse and dynamic.

Canadian pharma companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXVand CSE by year-to-date gains. All data was compiled on October 28, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$10 million at that time. Read on to learn about what's been driving their share prices.

1. Cipher Pharmaceuticals (TSX:CPH)

Company Profile

Year-to-date gain: 187.86 percent
Market cap: C$462.9 million
Share price: C$15.89

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF on January 29.

In addition to its current portfolio, Cipher has acquired Canadian rights multiple dermatology treatments currently undergoing Phase III clinical trials: MOB-015 for the treatment of nail fungus, and CF-101 for the management of moderate to severe plaque psoriasis. MOB-015 Phase III trial results are expected in January 2025, and a pivotal Phase III study for CF-101 is expected to start in 2024. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

On July 29, Cipher signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights. Natroba is a topical treatment for scabies and head lice, and it has FDA exclusivity for the scabies indication through 2033.

Cipher’s share price climbed significantly over the following month, which included the release of its Q2 results. Sales of Epuris, Cipher’s bioequivalent to Accutane, were up by 13 percent compared to Q2 2023, marking their fourth consecutive quarterly increase. However, its price took a hit in September on early blind results from the MOB-015 trials.

2. NurExone Biologic (TSXV:NRX)

Company Profile

Year-to-date gain: 123.73 percent
Market cap: C$35.85 million
Share price: C$0.66

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received an Orphan Drug Designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

During the release of NurExone’s Q1 results, the company shared it would be commencing human trials of ExoTPEN in 2025. On September 26, NurExone announced a non-brokered private placement of up to US$2 million, and reported it had closed the first tranche of US$1.61 million.

3. Satellos Bioscience (TSXV:MSCL)

Company Profile

Year-to-date gain: 86.67 percent
Market cap: C$91.84 million
Share price: C$0.84

Satellos is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

An acceptance to commence Phase 1 clinical trials of the drug was announced on August 19 and the first patient was dosed on September 18. Analysis of tests conducted on canines, shared on October 1, showed improved muscle morphology and increased muscle regeneration with no adverse side effects.

4. Telescope Innovations (CSE:TELI)

Press Releases Company Profile

Year-to-date gain: 79.17 percent
Market cap: C$23.36 million
Share price: C$0.43

Telescope Innovations is a chemical technology company that develops scalable manufacturing processes and tools that combine robotic automation, online analysis and machine learning for the pharmaceutical and chemical industries.

The company has commercialized its Direct Inject-LC system. Short for Direct Inject Liquid Chromatography, the system combines hardware and software to analyze chemical reactions and can potentially reduce the time and cost of new drug development.

On July 31, Telescope Innovations entered into a collaborative research agreement with pharma giant Pfizer (NYSE:PFE) to accelerate pharmaceutical research and development using automation, robotics and artificial intelligence.

According to a press release, some efforts will focus on deploying Self-Driving Laboratories, a concept pioneered by Telescope Innovations in which robotic systems carry out experiments while AI algorithms analyze the data in real-time to inform researchers about what the next steps should be. The release states that Self-Driving Laboratories are “capable of optimizing material properties and chemical synthesis methods up to 100x faster than traditional research methods.”

....... into Q1/Q2 2025

“We are pleased to enter into this relationship with Avenue Capital Group that provides what we believe is a shareholder-friendly financing for the Company,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen. “This additional working capital will support the clinical development of our three, first-in-class modifier gene therapies and provide adequate funding to near completion of the OCU400 Phase 3 liMeliGhT clinical trial and prepare for the BLA and MAA submissions.”

https://www.stocktitan.net/news/OCGN/ocugen-secures-30-million-in-debt-o5c72w8ih69k.htm

==================

USA Election nugget. The Vaccin Ocugen works on - is the type of Vaccin RFK DOES support. The OCGN Vaccin has been halted by FDA (many suspect Big Pharma push-back)

===================

• Ocugen Pipeline - Quick overview
  • Vaccin (the kind RFK does like)
    • Fully funded by NIAID (Headed by Fauci) . Ocugen retains ALL the rights to the Vaccin. NIAID expected to start a Phase 1 trial this year.
    • The vaccin is for INHALE - meaning easy to administer, AND stockpiling with LONG shelf-life.
    • https://medicine.wustl.edu/news/nasal-covid-19-vaccine-halts-transmission/
  • Eye portion
    • RMAT designation. Essentially speeds up trials and approvals.
    • EMA acceptance of USA trial results.
    • Extended trials into Canada
  • NEOCART
    • CEO stated once that the technology is not preferred by surgeons. He may have made a mistake here. But, at the other hand - this science has seen a phase 3 before, it missed endpoints nearly. Ocugen therefore has a road-map and knows exactly what is required to get it through PH3.

Earlier this year, MDGL (Madrigal Pharmaceuticals) announced the FDA approval of their groundbreaking Rezdiffra (Resmetirom) drug for NASH, marking the first approved treatment for this serious liver condition. Since then, MDGL’s stock has been on fire, especially following their latest financials at the end of October. The stock soared from $213 to as high as $368, showing just how much market demand there is for effective NASH treatments (see chart below).

https://preview.redd.it/kugrrr7ptjzd1.png?width=975&format=png&auto=webp&s=04544eab477e910d3fce7d93c9ea1099a535cc88

This is where Thiogenesis Therapeutics Corp. (TSXV: TTI) comes in as an emerging competitor with their lead compound, TTI-0102. Currently advancing in Phase 2 trials for NASH and other high-need metabolic and mitochondrial diseases, TTI-0102 is expected to release interim data and analysis in early 2025 – just a few months away!

https://preview.redd.it/sqx43mxytjzd1.png?width=1167&format=png&auto=webp&s=297c5485334d6545655713e5aa8182f2579a40f4

Here's why TTI-0102 stands out:

1. Multi-Disease Target: Unlike many single-target drugs, TTI-0102 shows potential across multiple severe and underserved conditions, including pediatric NASH, MELAS, Leigh Syndrome, and Rett Syndrome. This broader applicability gives TTI a diversified approach to treating metabolic and mitochondrial disorders, which are often linked to oxidative stress.
2. Unique Mechanism: TTI-0102 works by increasing intracellular glutathione, a critical antioxidant that helps combat cellular damage associated with these diseases. This mechanism is innovative in targeting the underlying metabolic dysfunction, making TTI-0102 a strong contender in the metabolic therapeutic space.
3. Experienced Management: The team behind TTI has a track record in rare and orphan drug development, with former roles in companies like Raptor Pharmaceuticals (acquired for $800 million) and BioMarin. Their experience boosts confidence in TTI’s ability to navigate the complex drug development and regulatory landscape successfully. (read executive's bios: https://www.thiogenesis.com/about)**Upcoming Catalysts**: In addition to interim results expected in early 2025 for NASH, TTI has multiple milestones on the horizon, including the start of Phase 2 trials for Leigh Syndrome and pediatric NASH and a Phase 2/3 trial for Rett Syndrome in the first half of 2025.

https://preview.redd.it/gb4w0j60ujzd1.png?width=657&format=png&auto=webp&s=b0e1420b6425de97135f3937f8064271269343e8

With its unique mechanism, experienced team, and upcoming clinical data, Thiogenesis Therapeutics (TTI) could be positioned to capitalize on the same high-demand market MDGL is already benefitting from. While TTI is still in the early stages compared to MDGL, the significant interest in NASH treatments and TTI’s potential pipeline diversity make it a compelling prospect to watch as Phase 2 data approaches.

Posted on behalf of Thiogenesis Therapeutics, Corp. 

I don't perceive any significant competitive advantages within Bayer's crop science segment compared to its competitors. Could you clarify where I might be mistaken or overlooking?

Now Diamyd medical AB shows what they knew from 2020. Namely, how much better results we can expect from the drug-founding study Diagnode-3.

Diamyd medical AB study medication has been administered to over 1,000 participants without side effects but a result just below a significant result.

First round until 2011 with administration just under the skin (subcutaneous).

In 2020, a retrospective study was done that showed that genetically only just under half of those diagnosed with insulin need can be treated with GAD-65.

https://mb.cision.com/Main/6746/3164267/1287422.pdf

Around 2017, new studies were started with administration in a lymph node. Diagnode-1 and Diagnode-2 were carried out before the publication of the genetic significance.

Diagnode-3 is conducted with only participants who are expected to respond to the treatment.

Today, Nov 7, they present at the congress in Belgium the numbers that make it easier to see what the final result of Diagnode-3 will be.

https://idsbruges2024.com/

And here's what you really want to read

”In-depth analysis showing robust Diamyd***^(®)*** treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress”

https://mb.cision.com/Main/6746/4061936/3096442.pd

With great probability, GAD-65 will be a tough competitor to Sanofi TZIELD.

Then Diamyd medical AB's valuation should be considered based on what Sanofi bought Bio Provention for.

DMYD can be a bit difficult to buy from the US.

https://finance.yahoo.com/quote/DMYD-B.ST/

Any ideas, it's election related I guess but I can't see why such an extra drop from last week?

This to me is the easiest flip on the Bio market. The premise is simple: Catalysts combined with massive cost cutting will make this 1,2$ -1,5$ in Q1 2025.

• FibroGen may be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 0.2x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 13.2x 

Looking at the StockTwits chat, I see some notorious names joining this thesis.

============================

• Quick overview of facts
  • 75% reduction in USA workforce
  • Chief Medical Doctor departure
  • Chief Financial Officer departure
    • Saving millions in payroll expenses
  • Cancel HQ
    • The above may indicate a sale of the company, the cost cutting is excessive. Saving approximately 20 million p/a
  • 150 million in cash (runway thru 2026)
    • Cash covers Covers debt
  • Increased revenue guidance
  • Expected Catalysts
    • China Indication approval with 10 Million milestone payment.
    • Partner for NEW Pipeline candidate (as indicated by management)
    • Positive earnings (which will include one-off liabilities)

======================================

• 'Through a joint venture between AZ and FibroGen, Evrenzo generated $284 million in sales in China in 2023, a healthy rate of 36% growth year over year. That translated into $101 million in revenue for FibroGen. Evrenzo is on target to reach 130 to 150 million in revenues for 2024. A 60% increase year on year' This has a 35m market cap doing 130m in revs for a single drug?
  • These revenues are increasing, however patents expire and generic drugs will flood the market.
  • New indication approval is expected.
    • Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024. If approved, FibroGen will receive a $10 million milestone payment from AstraZeneca.
  • Expectations China
    • For 2024, FibroGen expects Evrenzo’s China sales will continue to grow to a range from $300 million to $340 million despite a 7% price reduction from renewed coverage under the country’s national insurance scheme
  • Financial:
    • Second quarter total roxadustat net sales in China^(1) by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca (JDE) was $92.3 million, compared to $76.4 million in the second quarter of 2023, an increase of 21% year over year, driven by a 33% increase in volume.
    • Roxadustat continues to be the number one brand based on value share in the anemia of CKD market in China.
    • For 2024, FibroGen’s expected full year net product revenue under U.S. GAAP is raised to a range between $135 million to $150 million, representing expected full year roxadustat net sales in China^(1) by FibroGen and the JDE of $320 million to $350 million, due to continued strong performance in China.

NEW!!!!!!

• FibroGen Inc.'s senior leaders prevailed in litigation blaming them for the fallout of its failed effort to develop an anemia drug through a partnership with AstraZeneca Plc.A Delaware judge Wednesday dismissed claims that the board turned a blind eye to doctored clinical data, false statements by management, and a scheme by two executives to sell stock at inflated prices. The company’s broad liability shield limits fiduciary breach claims against the board to those involving bad faith, and there’s no reason to think its members deliberately ignored red flags, the judge said.
  • https://news.bloomberglaw.com/esg/fibrogen-board-beats-lawsuit-over-failed-astrazeneca-partnership
  • The company did not PR this. Why?
• FibroGen, a biopharmaceutical company focused on cancer therapy development, paid $10 million to terminate its lease for the entirety of the building at 409 Illinois St. in the city's Mission Bay area where it has been based for nearly two decades, according to information filed with the Securities and Exchange Commission.
  • Cancel HQ, makes me wonder: Will Astra buy FGEN (and therewith Rodux worldwide rights) contingent on indication approval? That would mean Astra would make 400-500 million per year ?

Hi there, I posted about this settlement already, but I just found out that Taro Pharma is accepting late claims on it and you can still file to get payment even if the deadline has passed.

If you missed it, back in 2016, Taro was accused of hiding its role in a generic drug price-fixing scandal. They allegedly were conspiring with competitor companies to fix the prices of at least seven different drugs (f. ex. Clobetasol and Desonide). 

The whole thing led to a big hit on $TARO stock when news about the DOJ’s antitrust investigation and an investor’s lawsuit came out.

The good news is that they recently agreed to a $36M settlement to end claims about hiding their role in this scandal.

So, if you purchased $TARO shares during this period, you may be eligible for a payout, so check out the details and file for it here.

Anyway, has anyone here had $TARO back then? If so, how much were your losses?

As Recursion Pharmaceuticals prepares for its upcoming earnings call, investors and analysts are closely watching for insights into the company’s growth trajectory and potential catalysts for stock performance. Recursion, known for its innovative approach to drug discovery through AI-driven and machine-learning methodologies, has captured significant interest in the biotech sector. With an earnings call on the horizon, questions about the company’s progress on key pipelines, partnership updates, and revenue outlook are top of mind for stakeholders.

A primary area of focus is likely to be updates on Recursion’s partnerships with major pharmaceutical companies. Any positive developments could signal increased revenue streams and broadened market potential, driving investor confidence. Additionally, insights into how Recursion has managed its research and development costs amidst high inflation will be closely examined, as efficient spending in this area could signal future financial stability. Analysts may also be looking for milestones achieved in clinical trials, which could potentially bring some of Recursion’s drug candidates closer to market.

The outcome of the call could have a significant impact on Recursion’s stock price. Positive news, especially related to successful clinical trial phases or new strategic partnerships, may result in a stock price rally. Conversely, any delays or setbacks could lead to increased volatility. Investors are eager to see if Recursion’s AI-powered platform continues to accelerate drug discovery and, ultimately, drives shareholder value. This earnings call may provide the clarity needed for a more defined outlook on Recursion’s future. How do y’all think this will impact the stock?

How do yall feel about ETFs with moderna? https://www.clinicaltrialsarena.com/analyst-comment/gsk-hsv-vaccine-moderna-biontech/ ... they could come out with a Cold Sore/ HSV 1&2 Cure. It looks like Moderna is low now, a buy and hold? Opinions?

​

https://preview.redd.it/yklhbf17hxxd1.jpg?width=300&format=pjpg&auto=webp&s=3a7e01bc1729691c6b357562f3f3f5cc8c9ca5fb

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024.

The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

Register for the Conference here.

Submit Questions for any of the presenting companies to:
Questions@EmergingGrowth.com

For updates, follow us on Twitter

Sponsors:
QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions
(844) 485-8200
Sales@QuoteMedia.com
QuoteMedia.com

MYNZ has teamed up with Petra Smeltzer to promote early detection of colorectal cancer with their ColoAlert test. Could this partnership help MYNZ make strides in the early cancer screening market? What other strategies could amplify their message?

Bullish trend a sign for more gains?

https://preview.redd.it/zs1sabx44rxd1.jpg?width=1454&format=pjpg&auto=webp&s=af856d67d7835137fc73555df0a43cfd7d45c18e

https://preview.redd.it/fsupvkmcxqxd1.jpg?width=1454&format=pjpg&auto=webp&s=059f2dadc5a67ffd73824b7f72e343570493fb03

$MYNZ soared to $0.28 today, up nearly 11%! It’s broken past resistance levels, showing strong bullish momentum. This stock is exceeding expectations in diagnostics—are you holding strong for future gains?

With a solid upswing into the afternoon, Mainz Biomed NV ($MYNZ) saw a notable intraday increase, closing up 8.48% at $0.28. The stock gained momentum at 1:00 PM, breaking resistance at $0.26 and hitting an intraday high of $0.28 after consolidating around $0.24 in the morning. Strong purchasing interest is indicated by the stock's high volume and quick gain during the past hour, most likely in anticipation of the company's upcoming earnings in early November. With a $5.99M market capitalization and a recent spike, $MYNZ might draw greater interest from the biotech industry.

https://preview.redd.it/8t6bwhjysqxd1.png?width=1428&format=png&auto=webp&s=c855658f30c109a3f3057c3eedceb7ae3185418e

​

https://preview.redd.it/yiezln9h1qxd1.png?width=386&format=png&auto=webp&s=07e39cf981089bc8daf6183533b8ebd62cbe01a4

Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders. One such therapy involves healing the central nervous system and brain through the regulation of serotonin.

https://preview.redd.it/rfgizjbm1qxd1.png?width=962&format=png&auto=webp&s=e1a83164c85791ddfd58c68303fb84d374a6cf12

As one afflicted with mild Absence Epilepsy, the Company has more than a passing interest.

Epilepsy

Let’s start here: Epilepsy is a brain disease where nerve cells don't signal properly, which causes seizures. Seizures are uncontrolled bursts of electrical activities that change sensations, behaviours, awareness and muscle movements.

Although epilepsy can't be cured yet, many treatment options are available.

DRUG recently announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101--a highly selective 5-HT2C receptor agonist--, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Agonists are drugs or naturally occurring substances that activate physiologic receptors, whereas antagonists block those receptors.

Make It So

The key aspects of DRUG’s provenance are fascinating. Proprietary systems, including scaffolding and BMB-101.

Ian McDonald, Chief Executive Officer of Bright Minds Biosciences, notes, "This compound is not only poised to make a significant impact in both the DEE and Absence Epilepsy communities but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance.” The key phrase in that quote is the 30% of epilepsy patients who are drug resistant.

Absence Epilepsy

A person without a seizure may stare blankly into space for a few seconds. Then, the person typically returns quickly to being alert. This type of seizure usually doesn't lead to physical injury, but injury can result during the period when the person loses consciousness. This aspect is particularly true if someone is driving a car or riding a bike during the seizure.

As I have this affliction, I can’t get a driver's licence or ride any motorized vehicle solo. Kind of a pain, but given the alternative happy to comply; cars are expensive. As a reformed smoker, I miss cigarettes as much as driving. But I digress.

Globally, an estimated 5 million people are diagnosed with epilepsy each year. In high-income countries, there are estimated to be 49 per 100,000 people diagnosed with epilepsy each year. This figure can be as high as 139 per 100,000 in low- and middle-income countries.

Help looks to be on the way through Bright Minds.

Scaffolds are implants commonly used to deliver cells, drugs, and genes into the body. Their regular porous structure ensures the proper support for cell attachment, proliferation, differentiated function, and migration.

Here’s the Wikipedia educational part;

Tissue engineering is a biomedical engineering discipline that combines cells, engineering, materials methods, and suitable biochemical and physicochemical factors to restore, maintain, improve, or replace different types of biological tissues. Tissue engineering often involves the use of cells placed on tissue scaffolds to form new viable tissue for a medical purpose, but is not limited to applications involving cells and tissue scaffolds. While it was once categorized as a sub-field of biomaterials, having grown in scope and importance, it can be considered a field of its own.

Other initiatives are compounds to address;

BMB-xxx Obesity and feeding behaviour

BMB-201 Treatment-resistant depression

BMB-202 Depression

Let's let DRUG explain its approach to psychedelics;

Psilocybin, which is the psychoactive and psychedelic compound found in magic mushrooms, may have the ability to reset the functional connectivity of brain circuits known to play a key role in major depressive disorder (MDD)  by its action on the 5-HT2A receptors. Unfortunately, because it is equally potent at the 5-HT2A and 5-HT2B receptors, the full potential of this compound cannot be achieved in MDD patients because of side effects. 

The Bright Minds Biosciences can ameliorate these targeted 5-HT2A and 5-HT2A/C agonists.

Even though I have an overactive personal interest in DRUGS—don't own any yet—have a look with a view to ownership in a small Pubco portfolio section.

Colorectal cancer rates in young people have surged, and Frankie Muniz is using his platform to raise awareness by partnering with $MYNZ. Their ColoAlert test offers high accuracy and early detection, which is critical for families. It’s a great reminder of how important preventive healthcare is, especially for the next generation.